Efficacity of Gefitinib or Erlotinib for EGFR- mutant advanced non-small cell lung carcinoma

Authors

  • Nader Abdullah Tishreen University

Abstract

tyrosine kinase inhibitors (TKIs) targeting the Epithelial growth factor receptor(EGFR) have fundamentally changed the treatment of metastatic NSCLC.

Gefitinib and erlotinib are first-generation EGFR-TKIs that have been shown to be effective in the treatment of EGFR mutation-positive, metastatic non-small-cell lung cancer compared with chemotherapy in all treatment lines.

This retrospective study aims to evaluate the efficacy of these two drugs in patients with metastatic non-small cell lung cancer (NSCLC) who are EGFR mutation positive in terms of Disease-free survival.

The study included 46 patients who attended the chemotherapy and radiotherapy center from November 2016 to December 2020 who had metastatic non-small cell lung cancer positive for EGFR mutation.

All patients were treated with one of the tow drugs gefitinib or erlotinib or sometimes alternately depending on the availability of drugs. The mean survival rate without recurrence, regardless of the treatment line, was 6.95 months (1-27 months) We found a better response when using drugs as a first line, where the average disease-free survival rate was 12.4 months (5-27 months). while the average in the second line was 6.32 months (1-17 months), and the average in the third line and beyond was 3.30 months (1-6) months.

Increased efficacy was observed in non-smokers with a statistically significant difference, while this difference was not statistically significant according to gender, age and histological type.

 Tyrosine kinase inhibitors (gefitinib and erlotinib) have very significant efficacy in EGFR-positive, metastatic NSCLC, especially when given as first-line therapy.

Author Biography

Nader Abdullah, Tishreen University

Associate Professor - Department of Oncology - Faculty of Human Medicine

Downloads

Published

2022-01-17

How to Cite

1.
عبدالله ن. Efficacity of Gefitinib or Erlotinib for EGFR- mutant advanced non-small cell lung carcinoma. Tuj-hlth [Internet]. 2022Jan.17 [cited 2024Nov.24];43(6):25-32. Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/11534

Issue

Vol. 43 No. 6 (2021): Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.